Effects of oligomerization on the epitopes of the human immunodeficiency virus type 1 envelope glycoproteins

被引:43
作者
Gorny, MK
VanCott, TC
Williams, C
Revesz, K
Zolla-Pazner, S
机构
[1] NYU, Sch Med, Dept Pathol, New York, NY 10016 USA
[2] Henry M Jackson Fdn Advancement Mil Med, Rockville, MD 20850 USA
[3] Vet Affairs Med Ctr, Res Ctr AIDS & HIV Infect, New York, NY 10010 USA
关键词
D O I
10.1006/viro.1999.0095
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
To understand the differential expression of epitopes on monomeric and oligomeric forms of the envelope glycoproteins, nine human monoclonal antibodies (mAbs) were derived from the cells of human immunodeficiency virus-infected subjects by selection with soluble oligomeric gp140 (o.140). These nine mAbs and 12 human mAbs selected with V3 peptides, viral lysates, and rgp120, specific for the V2, V3, C5, CD4-binding domain (CD4bd), and gp41, were tested in a binding assay to compare the exposure of these regions on monomeric gp120 or gp41 and on o.140 None of the 21 mAbs were oligomer specific. However, mAbs to vs and CD4bd were oligomer sensitive," whereas mAbs to V2 and the distal epitope of C5 tended to be "monomer sensitive" (i.e., to react better with the oligomer or monomer, respectively) The majority of anti-gp41 mAbs reacted similarly with monomer and oligomer. Although the uncleaved o.140 used in this study differs from the cleaved gp120/41 oligomer found on the native virus particle, these results suggest that new epitopes are not introduced by oligomerization of viral envelope proteins, that such oligomer-specific epitopes, if they exist, are not highly immunogenic, and/or that they are not efficiently selected using soluble o.140, (C) 2000 Academic Press.
引用
收藏
页码:220 / 228
页数:9
相关论文
共 49 条
  • [11] GORNY MK, 1993, J IMMUNOL, V150, P635
  • [12] Gorny MK, 1997, J IMMUNOL, V159, P5114
  • [13] PRODUCTION OF SITE-SELECTED NEUTRALIZING HUMAN MONOCLONAL-ANTIBODIES AGAINST THE 3RD VARIABLE DOMAIN OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ENVELOPE GLYCOPROTEIN
    GORNY, MK
    XU, JY
    GIANAKAKOS, V
    KARWOWSKA, S
    WILLIAMS, C
    SHEPPARD, HW
    HANSON, CV
    ZOLLAPAZNER, S
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (08) : 3238 - 3242
  • [14] GENERATION OF HUMAN MONOCLONAL-ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS
    GORNY, MK
    GIANAKAKOS, V
    SHARPE, S
    ZOLLAPAZNER, S
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (05) : 1624 - 1628
  • [15] HUMAN ANTI-V2 MONOCLONAL-ANTIBODY THAT NEUTRALIZES PRIMARY BUT NOT LABORATORY ISOLATES OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1
    GORNY, MK
    MOORE, JP
    CONLEY, AJ
    KARWOWSKA, S
    SODROSKI, J
    WILLIAMS, C
    BURDA, S
    BOOTS, LJ
    ZOLLAPAZNER, S
    [J]. JOURNAL OF VIROLOGY, 1994, 68 (12) : 8312 - 8320
  • [16] Gorny MK., 1994, CELL BIOL LAB HDB, V2, P276
  • [17] PROTEIN OLIGOMERIZATION IN THE ENDOPLASMIC-RETICULUM
    HURTLEY, SM
    HELENIUS, A
    [J]. ANNUAL REVIEW OF CELL BIOLOGY, 1989, 5 : 277 - 307
  • [18] Antigenicity of truncated forms of the human immunodeficiency virus type 1 envelope glycoprotein
    Jeffs, SA
    McKeating, J
    Lewis, S
    Craft, H
    Biram, D
    Stephens, PE
    Brady, RL
    [J]. JOURNAL OF GENERAL VIROLOGY, 1996, 77 : 1403 - 1410
  • [19] CHARACTERIZATION OF THE SECRETED, NATIVE GP120 AND GP160 OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1
    KALYANARAMAN, VS
    RODRIGUEZ, V
    VERONESE, F
    RAHMAN, R
    LUSSO, P
    DEVICO, AL
    COPELAND, T
    OROSZLAN, S
    GALLO, RC
    SARNGADHARAN, MG
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 1990, 6 (03) : 371 - 380
  • [20] A UNIQUE HUMAN IMMUNODEFICIENCY VIRUS CULTURE SECRETING SOLUBLE GP160
    KALYANARAMAN, VS
    PAL, R
    GALLO, RC
    SARNGADHARAN, MG
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 1988, 4 (05) : 319 - 329